Objectives: We present the results of two European external quality assessments (EQAs) conducted in 2014 and 2016 under the auspices of the Study Group on Staphylococci and Staphylococcal Infections of ESCMID. The objective was to assess the performance of participating centres in characterizing Staphylococcus aureus using their standard in-house phenotypic and genotypic protocols.
Introduction
A robust clinical evaluation of the reliability of the results provided by the microbiology laboratories to the clinician is essential for effective patient management. Quality control measures are important to ensure that the laboratory is proficient in performing the tests and services it provides. For most European clinical microbiology reference laboratories, this demands adherence to the common International Standard Organization (ISO) framework and in particular ISO15189, which sets out the quality management requirements for the European medical laboratory. 1 Accurate testing performed in accordance with best practice is an essential tool for risk management. External quality assessment (EQA) is crucial to control the analytical process and is required for ISO15189 accreditation.
In this study, we present the results of two European EQAs organized under the auspices of the Study Group on Staphylococci and Staphylococcal Infections (ESGS) of ESCMID in 2014 and 2016.
The objective of these EQAs was to assess the ability of laboratories to perform species identification, antimicrobial resistance detection, toxin gene profile determination and typing of Staphylococcus aureus using their own phenotypic and genotypic protocols.
Methods

Participants
The survey was co-ordinated by the National Reference Centre (NRC)-S. aureus, Université Libre de Bruxelles (ULB), Brussels, Belgium (A. Deplano 
Proficiency panel and testing
Two collections of well-characterized Staphylococcus clinical isolates comprising S. aureus (n " 9), Staphylococcus argenteus (n " 1) and Staphylococcus capitis (n " 1) (Table 1) were coded and distributed to the participating laboratories on November 2014 and January 2016. Laboratories were requested to analyse the collection using one of the two proposed panels (basic/extended) and to return results using a standardized template within 2 months.
The basic panel included species identification, determination of MICs of oxacillin, cefoxitin and mupirocin, detection of resistance genes (mecA, mecC and mupA) and toxin genes (lukS-PV and lukF-PV, tst, eta, etb and enterotoxin genes sea to see) and molecular typing by spa typing and/or MLST.
The extended panel included the basic panel and the following additional tests: (i) antimicrobial susceptibility profile to 16 antibiotics ( 
Data analysis
Data were returned electronically to the co-ordinating NRC. Data included information concerning: (i) methods used; (ii) phenotypic identification, MICs and antimicrobial susceptibility profiles; and (iii) genotypic characterization [presence/absence of target gene(s), spa type, SCCmec type and MLST profile/type]. The concordance with expected results was examined by the co-ordinating NRC that inspected number of correct results/number of total results. Laboratories were anonymized. A report including all results, analysis, conclusions and recommendations was sent to participating laboratories together with their assigned code.
Results
Participation
A total of 13 laboratories from 12 European countries participated in one or both EQAs. Of these, eight were NRCs for S. aureus located in Belgium, Denmark, England, France, Germany, Greece, Ireland and Romania. Other laboratories were from Denmark, Germany, Poland, Portugal and The Netherlands. Eleven laboratories participated in both EQAs. In each EQA survey, three laboratories performed the 'basic panel' and eight laboratories the 'extended panel' (Table S1 , available as Supplementary data at JAC Online).
Methods used
The methods used by the participating centres are shown in Table S1 .
Concordance with expected results
The expected results including phenotypic and genotypic characteristics of the two Staphylococcus species collections are presented in Table 1 .
Concordance (%) by test and participating centre in both EQAs are shown in Table 2 . Overall, concordance ranged from 90% to 100%: only the MIC of oxacillin and eta gene detection gave a concordance below 95% (Table 2) .
Excellent identification (95%) to species level was observed in both EQAs (Table 2 ). Of note, the S. argenteus strain (16-S-01) was misidentified as S. aureus by six laboratories in EQA 2016 (Table S2) . These laboratories used MALDI-TOF MS, PCR for nuc gene detection, Vitek2 or 16S rRNA sequencing (Table S1) .
A low discrepancy rate (1%) in antimicrobial susceptibility profiling (for 2 antibiotics) was observed in two laboratories in 2014 and four laboratories in 2016 (Table 2 and Table S1 ). These laboratories used disc diffusion (paper), Vitek2 or broth microdilution. In 2016, three laboratories did not report an MLS B inducible phenotype in two isolates (16-S-02 and 16-S-03).
For MIC determination, the MIC of cefoxitin proved concordant in all instances (Table 2) . A 9% discrepancy rate was observed for the MIC of oxacillin for the mecC-positive 14-S-04 strain, which showed low-level oxacillin resistance (MIC 4-16 mg/L) ( Table 1) . This strain was designated as susceptible (MIC 2 mg/L) by four European EQAs for Staphylococcus aureus characterization JAC laboratories (36%), three of which used Etest V R ; the other used broth microdilution (Tables S1 and S2 ). Discordances in oxacillin MICs were also observed for susceptible 16-S-03 and resistant 16-S-05 isolates in four laboratories using the Etest V R method (Tables S1 and S2 ). The single discordance in mupirocin MIC observed in laboratory 5 in 2016 was probably owing to the inversion of isolate 16-S-04 (mupirocin susceptible) and 16-S-05 (mupirocin resistant) (Table S2) .
For resistance gene detection, 100% concordance was found for mecA and mecC detection ( Table 2 ). Discordances were observed for mupirocin (n " 1) and tetracycline (n " 1) using WGS, for MLS (n " 3) using PCR and for aminoglycosides (n " 3) using PCR, WGS and microarray (Tables S1 and S2) .
Regarding toxin gene detection, discordances were observed for tst, eta and etb in laboratory 5 using WGS in 2014 and for lukS-PV, tst, eta and etb in laboratory 11 using WGS in 2014 and 2016 (Tables S1 and S2 ). For enterotoxin gene detection, discrepant results for sea, sec, sed and see were observed in five laboratories over both EQAs (Table 2 and Table S2 ). These laboratories used WGS (n " 2), PCR (n " 2) or microarray technology (n " 1) (Table S1 ).
The genes encoding arcA, seh and etd were used for the detection of USA300, USA400 and European CA-MRSA clone, respectively. Complete concordance was observed except for isolate 16-S-04 showing a discordant result for the seh gene by WGS (Table 2,  Tables S1 and S2) .
For spa typing, all results were concordant except for the S. argenteus isolate 16-S-01, which was reported as non-typeable by six laboratories (Table S2) .
Concerning SCCmec typing, except for laboratory 6 using PCR in 2014 and laboratory 11 using WGS in 2016, 100% concordance was found in 2014 and 2016 ( Table 2 ). Inversion of 14-S-03 and 14-S-05 isolates during analysis was the underlying cause of the error in laboratory 6. For 14-S-04 isolate carrying SCCmec XI, two laboratories deduced SCCmec type from genotypic characteristics such as the presence of the mecC gene.
When considering MLST analysis, 100% concordance was observed but single locus variants of ST121 and ST772 were not detected by three laboratories in EQA 2014 and one laboratory in 2016 (Tables S1 and S2 ). These single locus variants included new aroE alleles 441 and 87 showing only one nucleotide difference (.99.8% homology) with aroE alleles 5 and 1, respectively (Table 1) .
Discussion
This initiative represents the first European EQA schemes to include identification, detection of antimicrobial resistance and virulence, and typing of S. aureus. Few EQAs for S. aureus have been reported previously and included only identification and molecular typing. [2] [3] [4] In the present broader-ranging EQAs, despite the use of quite disparate methods by participating centres, excellent concordance Table 1 . Characteristics of the EQA collections including S. aureus (n " 9), S. argenteus (n " 1) and S. capitis (n " 1) according to NRC-S. aureus, ULB Resistance and virulence genes examined: mecA, mecC, mupA, tet(K), tet(M), erm(A), erm(C), aac-aphD, aph3, aadC, lukS-PV, tst, eta, etb, etd, sea, seb, sec, sed, see, seh and arcA. c New aroE allele 441 showed .99% similarity to aroE allele 5. d New aroE allele 87 showed .99% similarity to aroE allele 1.
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with expected results was observed for identification, MICs of cefoxitin and mupirocin, detection of mecA, mecC, mupA and PVL genes and molecular typing including arcA, seh and etd detection, SCCmec determination, spa typing and MLST analysis. All isolates (apart from one isolate of S. argenteus) were correctly speciated by the participating laboratories. The S. argenteus isolate was misidentified as S. aureus by 55% of the laboratories using MALDI-TOF MS, 16S rRNA sequencing or nuc gene detection. This was previously described and highlights the challenge in accurately identifying this newly described species that is closely related genetically to S. aureus. 5, 6 S. argenteus could be identified by MALDI-TOF MS if the S. argenteus profile was added to the MALDI database 6 or by checking whether the spa type or MLST ST is one of those related to S. argenteus, for example t5787or t6675, ST2250 or ST2198. 5, 7 Regarding antimicrobial susceptibility, 36% of participating laboratories did not detect the low level of resistance to oxacillin, thus confirming the difficulty in detecting mecC-positive strains phenotypically by oxacillin. In contrast, the use of genotypic methods such as PCR or microarrays allowed accurate detection of these strains. If genotypic methods are not available, immunochromatography for PBP2a detection after induction is a valuable method (Test Alere). 8, 9 The susceptibility testing for most of antimicrobials allowed correct classification but an inducible MLS B phenotype was reported as clindamycin susceptible by three of eight laboratories in the EQA 2016, raising the question of how to report these phenotypes to clinicians. These inducible MLS B isolates were not recognized by classical testing but can be detected by antagonism of clindamycin activity by a macrolide agent such as erythromycin (The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. http://www.eucast.org).
WGS-based analyses proved accurate for molecular typing including spa typing, SCCmec typing and MLST, which is in accordance with a recently reported multicentre ring trial. 10 However, discrepancies for resistance, toxin and enterotoxin gene detection were observed in some centres using WGS technology. These inconsistencies underline the importance of harmonization and robust validation of WGS, particularly the bioinformatics pipelines, analytical processes and use of clinically validated databases.
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For molecular typing, a high level of concordance with expected results was obtained despite some minor issues. S. argenteus was found non-typeable by spa typing in six laboratories as previously reported (http://saureus.mlst.net). S. argenteus was classified as SCCmec type XI instead of type IV by one laboratory, which could be prevented by assessing consistency with other results, as SCCmec type XI is generally associated with clonal complex 130 containing the mecC gene. 8, 12 For MLST, new aroE alleles including an SNP were not identified by two and three laboratories in each EQA.
In conclusion, a good concordance (90%-100%) with expected results was observed despite the use of quite disparate techniques and protocols. The overall results provide a salutary note for centres using WGS to ensure that, for gene detection in particular, algorithms need to be carefully and robustly validated before being used routinely for clinical diagnostic purposes. In summary, we strongly advise all national reference laboratories and laboratories acting as referral centres participate in EQA schemes. 
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